Business Context and Reporting Period
Company: iBio, Inc. (IBIO)
Filing Type: Form 8-K (Current Report)
Date of Report: January 8, 2026
Event: Entry into a Material Definitive Agreement for a private placement of securities.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than operational financial results. Key transaction metrics include:
- Gross Proceeds: Approximately $26 million.
- Securities Issued:
- 1,408,481 shares of Common Stock.
- Pre-funded warrants to purchase up to 9,653,257 shares of Common Stock.
- Pricing:
- Common Stock: $2.35 per share.
- Pre-Funded Warrants: $2.349 per warrant (exercise price of $0.001).
- Expected Closing Date: On or about January 13, 2026.
- Placement Agents: Leerink Partners LLC (lead), LifeSci Capital LLC, and Oppenheimer & Co. Inc. (co-agents).
Note: The filing does not provide current revenue, profit, cash flow, or debt figures. These metrics are not applicable to this specific transaction report.
Material Changes and Use of Proceeds
The primary material change is the agreement to raise capital to fund operations and development. The Company intends to use net proceeds for:
- Advancing preclinical cardiometabolic programs, specifically IBIO-610, IBIO-600, and myostatin/activin A bispecific programs.
- Progressing other preclinical pipeline assets.
- Funding working capital requirements and general corporate purposes.
Guidance, Risks, and Contractual Restrictions
Contractual Restrictions (Lock-up): The Purchase Agreement prohibits the Company from issuing additional Common Stock or equivalents, effecting reverse stock splits, or filing new registration statements (with limited exceptions) until the earlier of 60 days after the Closing Date or the business day following the effectiveness of the Resale Registration Statement.
Registration Rights: The Company must file a resale registration statement within 60 days of closing and use commercially reasonable efforts to make it effective by the 75th calendar day if reviewed by the SEC.
Risks and Forward-Looking Statements: The filing contains forward-looking statements regarding the closing date and proceeds. Actual results may differ due to risks detailed in the Company's 10-K (fiscal year ended June 30, 2025) and 10-Q (quarter ended September 30, 2025).
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting placement agent commissions and offering expenses.
- Confirm the filing and effectiveness date of the Resale Registration Statement for the new shares and warrants.
- Review the Company's most recent 10-Q (filed November 12, 2025) for current cash position and burn rate to assess runway extension from the $26 million raise.
- Monitor the 60-day lock-up period expiration for potential dilution from future issuances.
- Check for any updates on the preclinical status of IBIO-610 and IBIO-600 programs.